Continuing Education Activity

Human immunodeficiency virus (HIV) encephalitis is a neurological condition caused by the direct impact of HIV on the central nervous system. This condition typically presents a spectrum of neurocognitive impairments, including memory deficits, motor dysfunction, and behavioral changes. The condition arises from inflammation and neuronal damage due to HIV invasion of brain tissue and frequently coexists with other complications of advanced HIV, such as opportunistic infections, making diagnosis challenging. Prompt administration of antiretroviral therapy is the cornerstone of treatment, reducing viral replication and mitigating disease progression. Left untreated, HIV encephalitis can significantly impair quality of life and lead to severe disability or death.

The course enables participants to identify the clinical features of HIV encephalitis, differentiating it from other neurocognitive conditions and implementing evidence-based treatment protocols. The course also provides in-depth knowledge of diagnostic techniques, including neuroimaging and laboratory analysis, to rule out opportunistic infections and confirm the diagnosis. Collaboration with an interprofessional team, including infectious disease specialists, neurologists, nurses, and mental health professionals, is emphasized, as this is crucial for comprehensive patient care. Such teamwork ensures accurate diagnosis, coordinated management plans, and ongoing support for patients, ultimately improving clinical outcomes and quality of life for those affected by HIV encephalitis.

Objectives:

• Identify the etiology and pathophysiological processes involved in developing human immunodeficiency virus encephalitis.
• Assess the clinical presentation of a patient with human immunodeficiency virus encephalitis.
• Apply the diagnostic modalities and treatment options for human immunodeficiency virus encephalitis.
• Communicate the importance of collaboration among the interprofessional team in identifying and appropriately managing patients with human immunodeficiency virus encephalitis.

Introduction

Human immunodeficiency virus (HIV) encephalitis, also referred to as HIV-associated neurological disorder, includes a range of neurocognitive defects of varying severity following HIV infection. The clinical presentation of this condition varies from asymptomatic or minor neurocognitive impairment to severe dementia. HIV encephalopathy, also known as acquired immunodeficiency syndrome-dementia complex, lies at the most severe end of this spectrum. The diagnosis is based on clinical neuropsychiatric evaluation and radiological studies. Prompt and effective administration of antiretroviral therapy is the most effective therapy in managing HIV encephalitis.

Etiology

The exact mechanism by which HIV infection leads to HIV encephalitis is not entirely clear.[1] A genetic basis for HIV encephalitis has also been studied, with the presence of an E4 allele for apoE being associated with an increased risk of neurocognitive damage.[2] However, some study results have demonstrated no proven association between the presence or absence of genetic polymorphisms and the prevalence of HIV encephalitis.[3] A low cluster of differentiation (CD)4 count and high plasma viral load are the key factors determining the development of HIV encephalitis. The patient's age at seroconversion is another important determinant, with patients in older age groups having an increased prevalence of cognitive deficits compared to younger populations. The presence of various comorbidities in older populations, such as insulin resistance and obesity, also contributes to an extent.

Epidemiology

The neurological disease spectrum in patients with HIV infection can be attributed to various causes, such as opportunistic infections of the central nervous system (CNS), polyneuropathies, spinal cord pathologies, and HIV encephalitis. In the United States, where antiretroviral therapy is widely accessible, the neurologic symptoms in patients with HIV disease are often due to HIV encephalitis. On the other hand, in developing countries where access to HIV treatment still demands improvement, neurologic deterioration is often implicated in opportunistic CNS infections such as toxoplasmosis and cryptococcosis, to name a few. No preponderance in sex has been observed relative to HIV encephalitis.

There has been a significant decrease in the severity of HIV encephalitis over the years, owing to the advent and widespread usage of antiretroviral therapy (ART).[4] But, even in the setting of ART, almost half of HIV-infected individuals have been shown to have mild to moderate neurocognitive dysfunction during their illness.[5][6] However, the presence of other comorbidities such as substance use disorder, diabetes, hypertension, and the effects of aging prevents clinicians from obtaining a clear estimate of the degree of cognitive deficits that can be exclusively attributed to HIV encephalitis.

Pathophysiology

Direct damage of central nervous system tissue due to HIV combined with activated immune responses to infection has been implicated in causing the neurocognitive decline associated with HIV encephalitis. HIV infection results in rapid virus seeding in various body premises, including CNS tissues, which are usually asymptomatic. Following infection with HIV, monocytes circulating in the blood migrate to the brain after traversing the blood-brain barrier, thus enabling HIV to gain access to the central nervous system. The entry of HIV into brain tissue through brain endothelium is believed to be aided by the induction of vascular cell adhesion molecule 1 and E-selectin. Though the direct impact of HIV on neurocognitive dysfunction after further development of distinct genetic sequences has been studied, a significant impact has been attributed to the indirect immune pathways triggered after viral entry into brain tissue.[7]

The release of monocyte-derived cytokines such as interleukin-1, tumor necrosis factor-α, and transforming growth factor-β, which trigger neurotoxic changes, is believed to be the more damaging entity in the pathophysiology of HIV encephalopathy.[8] Increased levels of monocytic chemotactic protein-1 in cerebrospinal fluid (CSF) have been shown to correlate with the severity of HIV encephalopathy. The compartmentalization of HIV infection in the CNS also plays a crucial role in developing HIV encephalitis.

After the virus's initial development from the circulating CD4 cells, CSF viral replication occurs independently of plasma viral replication in later stages of infection. A change in the tropism of the CNS viruses in the later stages of the disease also worsens the severity of the illness.  Several factors determine the neurological deterioration in HIV encephalitis. The production of neurotoxic HIV proteins, uncontrolled viral replication in brain tissue, and immune activation are underlying factors controlling the rate of neurological decline.[9]

Histopathology

Although HIV encephalitis can involve any part of the brain, pathologic changes such as pallor and gliosis are most often noted in the basal ganglia and nigrostriatal areas in the initial stages of the illness. These changes can be identified as early as within 1 year of the development of HIV encephalitis.[10] Later stages involve diffuse cerebral involvement, particularly in the temporal and frontal regions.

In these areas, microglial cells are stimulated by the virus to fuse and form multinucleated microglial cells. Perivascular infiltrates are often seen. This resultant subcortical microglial nodule encephalitis is pathognomic for HIV encephalitis. The effect of HIV on astrocytes and oligodendrocytes has also been identified, but the pathologic significance of this cellular affliction has not been demonstrated.[11]

History and Physical

History

The classical presentation of HIV encephalitis presents in a waxing and waning pattern rather than a progressive deterioration, as noted in conditions such as Alzheimer disease. Though HIV encephalitis is usually considered a late manifestation of HIV disease, it has also been known to occur in patients with CD4 counts of more than 350 cells/μL. The elucidation of symptoms that show a cognitive decline from the previous level indicates the presence of HIV encephalitis. Subcortical deficits such as psychomotor retardation, decreased concentration, and attention are often the hallmark of the presentation of this disease. An increase in forgetfulness and difficulty in performing complex tasks may also be noted often. Later stages of the disease may present with bowel or bladder complaints.

Physical Examination

Motor abnormalities such as tremors, gait, and balance disturbances are often demonstrated along with increased deep tendon reflexes and muscle tone. The Mini-Mental Status Examination is performed to objectively establish the cognitive function of individuals and compare it to earlier scores to check for deterioration.[12] The absence of cortical dysfunction signs such as agnosia, apraxia, and aphasia points away from the diagnosis of cortical dementia, such as Alzheimer disease, and substantiates the diagnosis of HIV encephalitis.

Clinical staging of HIV encephalitis is based mainly on the combined neurocognitive and functional status of the patient. The 3 main stages are namely, asymptomatic (neurocognitive status of 1 standard deviation [SD] below mean in 2 cognitive domains with no impairments in activities of daily living), mild (neurocognitive status of 1 SD below mean in 2 cognitive domains with impairments in activities of daily living) and HIV-associated dementia (neurocognitive status of 2 SD below mean in 2 cognitive domains with notable impairments in activities of daily living).

Evaluation

Lab Studies

CSF analysis by lumbar puncture plays an important role in evaluation. An increase in CSF protein, cell count, and the identification of HIV ribonucleic acid in CSF are all noted but are often non-specific findings related to HIV encephalopathy. In patients with HIV infection presenting with neurologic problems, CSF analysis helps rule out other opportunistic infections. The role of HIV culture in cerebral tissue samples of patients with HIV encephalitis has been extensively studied, with HIV cultures obtained from nerve, CSF, and brain tissues yielding positive results. However, this culture positivity has been noted in all the stages of HIV infection and does not correlate with the presence or absence of neurological symptoms or signs. Testing for CSF HIV viral levels and drug resistance is not routinely performed. An extensive metabolic panel needs to be undertaken in these patients to rule out conditions related to thyroid disease, folate, B12, syphilis, and hepatic disorders—which can present with a similar neurologic presentation. 

Radiology

Neuroimaging studies in patients suffering from HIV encephalopathy usually show cerebral atrophy on computed tomography or magnetic resonance imaging. In advanced stages of the disease, on T2-weighted sequences, multiple symmetric foci of hyperintense, non-enhancing lesions are seen predominantly in a subcortical distribution.[13]

Treatment / Management

The only proven option in managing HIV encephalitis, highly active antiretroviral therapy has proven to be of benefit in patients with HIV encephalitis, with significant improvements demonstrated in neuropsychiatric and cognitive test scores. The treatment has been shown to decrease and effectively reverse the pathologic damage caused by HIV clinically and radiographically. Antiretroviral therapy (ART) also helps to delay or prevent the onset of neurocognitive impairment in patients with HIV disease.[14] The effectiveness of ART in these patients has led to a decrease in the prevalence of severity of HIV encephalopathy, with a notable decrease in the number of cases of AIDS-dementia complex and an increased prevalence in the milder presentation of this disease.[15] ART has shown to be of clear benefit in patients presenting with HIV-associated dementia, whereas patients with milder cognitive impairment have not demonstrated any significant improvement.[16]

Drug regimens with higher CNS penetrance have been proven to be of better effect in managing patients with HIV encephalitis.[17] Tailoring treatment after considering both the CNS penetrance effect and the individual patient profile can provide optimum patient benefit. Efavirenz is usually not preferred in neurocognitive disorders owing to its many neuropsychiatric adverse effects. In patients diagnosed with HIV-associated dementia in whom initiation of ART is planned, the preferred regimen is tenofovir, dolutegravir plus emtricitabine, or a combination of lamivudine, abacavir plus dolutegravir. Drugs such as lithium, memantine, and minocycline have not proven beneficial in patients with HIV encephalitis.[18][19][20]

Differential Diagnosis

The differential diagnoses for HIV encephalitis include the following:

• Primary CNS lymphoma: This can also present with cognitive decline, memory loss, and motor symptoms such as hemiparesis. However, there are usually constitutional symptoms such as night sweats and fever. Imaging helps in differentiating between the 2 entities. Primary CNS lymphoma presents as mass lesions predominantly in the periventricular regions.
• Progressive multifocal leukoencephalopathy: This rapidly progressive demyelinating disorder is seen in immunosuppressed individuals. Caused by the John Cunningham virus, it can present with hemiparesis, ataxia, and memory loss. Magnetic resonance imaging shows bilateral, asymmetric foci of demyelination without mass effect in the periventricular and subcortical regions.
• Opportunistic infections: These include cryptococcosis and toxoplasmosis, which can be differentiated from HIV encephalitis by the associated clinical features, such as seizures. On imaging, both cryptococcus and toxoplasmosis show focal enhancing lesions with a mass effect. Cryptococcus can also present as meningitis, and toxoplasmosis leads to brain abscess.
• Nutritional deficiencies: Vitamin B12 and folate deficiency disorders must be ruled out.

Prognosis

Without the administration of ART, the acquired immunodeficiency syndrome-dementia complex can be fatal within 1 year. ART helps slow the disease's progression and increases life expectancy in patients. Older patient age and poor adherence to ART are the factors that are usually responsible for poorer outcomes in these patients.[21] The type of ART administration also determines the mode and severity of neuropsychiatric symptom patterns. Some study results have demonstrated that the use of combination ART compared to a single drug ART has shown improvements in visuospatial orientation and attention but a regression in learning efficiency.[22] The presence of even asymptomatic or mild neurocognitive impairment at baseline is an indicator of future neurologic decline. Some study results have demonstrated that even in this era of ART, the presence of neurocognitive deficits in a patient with HIV infection is a marker for increased mortality.[23]

Complications

The implementation of ART usage primarily determines the course of illness and complications in patients with HIV encephalitis. A rare condition termed CNS viral escape syndrome has been demonstrated in ART-treated individuals. This condition presents with new-onset neurocognitive defects, and lab studies demonstrate high CSF viral replication despite low plasma viral levels.[24]

Deterrence and Patient Education

ART administration should be considered promptly after the diagnosis of HIV disease owing to its beneficial effect. Emphasis should be placed on the importance of adherence to ART, potentially leading to significantly better patient outcomes.

Pearls and Other Issues

Key facts to keep in mind about HIV encephalitis are as follows:

• The initial stages of HIV encephalopathy are often similar in presentation to depression, fatigue, or Alzheimer disease and should be carefully differentiated.
• A baseline Mini-Mental Status Exam should be established for all patients in whom HIV infection has been diagnosed.
• CSF analysis following lumbar puncture plays a crucial role in ruling out the diagnoses of opportunistic infections.
• Patients with HIV encephalopathy demonstrate increased sensitivity to neuroleptic drugs; therefore, patients with HIV encephalopathy who receive these drugs should be monitored carefully, as they have an increased risk of developing extrapyramidal adverse events.

Enhancing Healthcare Team Outcomes

When caring for a patient with HIV encephalitis, an interprofessional healthcare team approach is best suited to driving better patient outcomes. This team includes clinicians, specialists, pharmacists, and nurses, collaborating and communicating across individual disciplines to ensure optimal care. A consultation with an infectious disease specialist for prompt and efficient ART administration and a neurological consultation for careful evaluation and monitoring of neurocognitive functioning provide the most benefit in managing patients with HIV encephalitis. ART administration is the most critical factor determining outcomes in patients with HIV encephalitis.[25]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK., CHARTER Group. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 Jun 10;82(23):2055-62. [PMC free article: PMC4118496] [PubMed: 24814848]

2.

Wendelken LA, Jahanshad N, Rosen HJ, Busovaca E, Allen I, Coppola G, Adams C, Rankin KP, Milanini B, Clifford K, Wojta K, Nir TM, Gutman BA, Thompson PM, Valcour V. ApoE ε4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60. J Acquir Immune Defic Syndr. 2016 Dec 01;73(4):426-432. [PMC free article: PMC5085854] [PubMed: 27228100]

3.

Levine AJ, Service S, Miller EN, Reynolds SM, Singer EJ, Shapshak P, Martin EM, Sacktor N, Becker JT, Jacobson LP, Thompson P, Freimer N. Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. Am J Med Genet B Neuropsychiatr Genet. 2012 Sep;159B(6):669-83. [PMC free article: PMC3418456] [PubMed: 22628157]

4.

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 Jul 26;372(9635):293-9. [PMC free article: PMC3130543] [PubMed: 18657708]

5.

Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I., CHARTER Group. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015 Feb 01;60(3):473-80. [PMC free article: PMC4303775] [PubMed: 25362201]

6.

Sheppard DP, Iudicello JE, Bondi MW, Doyle KL, Morgan EE, Massman PJ, Gilbert PE, Woods SP. Elevated rates of mild cognitive impairment in HIV disease. J Neurovirol. 2015 Oct;21(5):576-84. [PMC free article: PMC4618099] [PubMed: 26139019]

7.

McGuire JL, Gill AJ, Douglas SD, Kolson DL., CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol. 2015 Aug;21(4):439-48. [PMC free article: PMC4511078] [PubMed: 25776526]

8.

Guha D, Wagner MCE, Ayyavoo V. Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. J Neuroinflammation. 2018 Apr 27;15(1):126. [PMC free article: PMC5923011] [PubMed: 29703241]

9.

Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, Letendre SL, Ellis RJ, Grant I, Moore DJ., HIV Neurobehavioral Research Program (HNRP) Group. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014 Feb 01;65(2):190-7. [PMC free article: PMC3907119] [PubMed: 24442225]

10.

Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2003 Apr;13(2):195-210. [PMC free article: PMC4842209] [PubMed: 12744473]

11.

Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, Schlautman JD, Ciborowski P, Volsky DJ, Gendelman HE. HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol. 2008 Sep;3(3):173-86. [PMC free article: PMC2579774] [PubMed: 18587649]

12.

Nir TM, Jahanshad N, Busovaca E, Wendelken L, Nicolas K, Thompson PM, Valcour VG. Mapping white matter integrity in elderly people with HIV. Hum Brain Mapp. 2014 Mar;35(3):975-92. [PMC free article: PMC3775847] [PubMed: 23362139]

13.

Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011 Oct;53(8):836-42. [PMC free article: PMC3174098] [PubMed: 21921226]

14.

Chan P, Hellmuth J, Spudich S, Valcour V. Cognitive Impairment and Persistent CNS Injury in Treated HIV. Curr HIV/AIDS Rep. 2016 Aug;13(4):209-17. [PMC free article: PMC4977199] [PubMed: 27188299]

15.

Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016 Jan 26;86(4):334-40. [PMC free article: PMC4776086] [PubMed: 26718568]

16.

Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010 Jun 01;24(9):1243-50. [PubMed: 19996937]

17.

Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014 Apr;58(7):1015-22. [PMC free article: PMC3952601] [PubMed: 24352352]

18.

Decloedt EH, Freeman C, Howells F, Casson-Crook M, Lesosky M, Koutsilieri E, Lovestone S, Maartens G, Joska JA. Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore). 2016 Nov;95(46):e5401. [PMC free article: PMC5120936] [PubMed: 27861379]

19.

Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA., Adult AIDS Clinical Trial Group (ACTG) 301. 700 Teams. HIV MRS Consortium. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007 Sep 12;21(14):1877-86. [PubMed: 17721095]

20.

Nakasujja N, Miyahara S, Evans S, Lee A, Musisi S, Katabira E, Robertson K, Ronald A, Clifford DB, Sacktor N. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology. 2013 Jan 08;80(2):196-202. [PMC free article: PMC3589188] [PubMed: 23269596]

21.

Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, Conant K, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Marder K, Epstein LG. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007 Jan;64(1):97-102. [PubMed: 17210815]

22.

Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS. 2004 Jan 01;18 Suppl 1:S75-8. [PubMed: 15075501]

23.

Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010 Sep 28;75(13):1150-8. [PMC free article: PMC3013488] [PubMed: 20739646]

24.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012 Sep 10;26(14):1765-74. [PMC free article: PMC3881435] [PubMed: 22614889]

25.

Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, Kronborg G, Larsen CS, Obel N. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011 Jan 15;52(2):235-43. [PubMed: 21288850]

Disclosure: Vasudev Malik Daliparty declares no relevant financial relationships with ineligible companies.

Disclosure: Rashmi Balasubramanya declares no relevant financial relationships with ineligible companies.